Insmed reported $-98173000 in EBITDA for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebitda Change
DBV Technologies DBVT:US -13640000 3.49M
Acelrx Pharmaceuticals ACRX:US $ -8.57M 0.86M
Alimera Sciences ALIM:US $ -3.46M 1.36M
Biomarin Pharmaceutical BMRN:US $ 56.67M 96.56M
Cytokinetics CYTK:US $ -76.52M 58.35M
Dynavax Technologies DVAX:US $ 32.46M 49.7M
Gilead Sciences GILD:US $ 3422M 1947M
Heron Therapeutics HRTX:US $ -62.2M 9.46M
Insmed INSM:US $ -98173000 1.78M
Mirati Therapeutics MRTX:US $ -183.59M 12.92M
Novartis NVS:US $ 4552M 346M
Ophthotech OPHT:US $ -34.65M 1.57M
Regeneron Pharmaceuticals REGN:US $ 1360.9M 1353.3M
Sarepta Therapeutics SRPT:US $ -76.16M 19.51M
Seattle Genetics SGEN:US $ -115.96M 37.85M
Ultragenyx Pharmaceutical RARE:US $ -132.54M 33.51M
Vertex Pharmaceuticals VRTX:US $ 1069.3M 159.74M